Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Metabolic Rewiring and Altered Glial Differentiation in an iPSC-Derived Astrocyte Model Derived from a Nonketotic Hyperglycinemia Patient

  • Arribas-Carreira, Laura
  • Castro, Margarita
  • García, Fernando
  • Navarrete, Rosa
  • Bravo-Alonso, Irene
  • Zafra, Francisco
  • Ugarte, Magdalena
  • Richard, Eva
  • Pérez, Belén
  • Rodríguez-Pombo, Pilar
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., The pathophysiology of nonketotic hyperglycinemia (NKH), a rare neuro-metabolic disorder associated with severe brain malformations and life-threatening neurological manifestations, remains incompletely understood. Therefore, a valid human neural model is essential. We aimed to investigate the impact of GLDC gene variants, which cause NKH, on cellular fitness during the differentiation process of human induced pluripotent stem cells (iPSCs) into iPSC-derived astrocytes and to identify sustainable mechanisms capable of overcoming GLDC deficiency. We developed the GLDC27-FiPS4F-1 line and performed metabolomic, mRNA abundance, and protein analyses. This study showed that although GLDC27-FiPS4F-1 maintained the parental genetic profile, it underwent a metabolic switch to an altered serine–glycine–one-carbon metabolism with a coordinated cell growth and cell cycle proliferation response. We then differentiated the iPSCs into neural progenitor cells (NPCs) and astrocyte-lineage cells. Our analysis showed that GLDC-deficient NPCs had shifted towards a more heterogeneous astrocyte lineage with increased expression of the radial glial markers GFAP and GLAST and the neuronal markers MAP2 and NeuN. In addition, we detected changes in other genes related to serine and glycine metabolism and transport, all consistent with the need to maintain glycine at physiological levels. These findings improve our understanding of the pathology of nonketotic hyperglycinemia and offer new perspectives for therapeutic options., This research was funded by the Instituto de Salud Carlos (ISCIII), the European Regional Development Fund [PI22/00699]. The institutional grant of the Fundación Ramón Areces (Madrid, Spain) is also acknowledged. Laura Arribas-Carreíra was funded by the Asociación Española Para el Estudio de Enfermedades Metabólicas Congénitas (AEPEMEC)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Transcriptomic analysis identifies dysregulated pathways and therapeutic targets in PMM2-CDG

  • Gallego, Diana
  • Serrano, Mercedes
  • Cordoba-Caballero, Jose
  • Gámez, Alejandra
  • Seoane, Pedro
  • Perkins, James R.
  • Ranea, Juan A.G.
  • Pérez, Belén
PMM2-CDG (MIM # 212065), the most common congenital disorder of glycosylation, is caused by the deficiency of phosphomannomutase 2 (PMM2). It is a multisystemic disease of variable severity that particularly affects the nervous system; however, its molecular pathophysiology remains poorly understood. Currently, there is no effective treatment. We performed an RNA-seq based transcriptomic study using patient-derived fibroblasts to gain insight into the mechanisms underlying the clinical symptomatology and to identify druggable targets. Systems biology methods were used to identify cellular pathways potentially affected by PMM2 deficiency, including Senescence, Bone regulation, Cell adhesion and Extracellular Matrix (ECM) and Response to cytokines. Functional validation assays using patients' fibroblasts revealed defects related to cell proliferation, cell cycle, the composition of the ECM and cell migration, and showed a potential role of the inflammatory response in the pathophysiology of the disease. Furthermore, treatment with a previously described pharmacological chaperone reverted the differential expression of some of the dysregulated genes. The results presented from transcriptomic data might serve as a platform for identifying therapeutic targets for PMM2-CDG, as well as for monitoring the effectiveness of therapeutic strategies, including pharmacological candidates and mannose-1-P, drug repurposing., This work was funded the Instituto de Salud Carlos (ISCIII), European Regional Development Fund [PI22/00699] to BP. The Spanish Ministry of Economy and Competitiveness (grants PID2019-108096RB-C21 and PID2022-140047OB C21), the Institute of Health Carlos III (project IMPaCT-Data, exp. IMP/00019), co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”); and the European Union (HORIZON-HLTH-2022-DISEASE-06, Project ID: 101080580) to JAGR. The “CIBER de Enfermedades Raras” is an initiative from the ISCIII (Spain).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

HepG2 PMM2-CDG knockout model: A versatile platform for variant and therapeutic evaluation

  • Vilas, Alicia
  • Briso-Montiano, Álvaro
  • Segovia-Falquina, Cristina
  • Martín-Martínez, Arturo
  • Soriano-Sexto, Alejandro
  • Gallego, Diana
  • Ruiz-Montés, Vera
  • Gámez, Alejandra
  • Pérez, Belén
Phosphomannomutase 2 deficiency (PMM2-CDG), the most frequent congenital disorder of glycosylation, is an autosomal recessive disease caused by biallelic pathogenic variants in the PMM2 gene. There is no cure for this multisystemic syndrome. Some of the therapeutic approaches that are currently in development include mannose-1-phosphate replacement therapy, drug repurposing, and the use of small chemical molecules to correct folding defects. Preclinical models are needed to evaluate the efficacy of treatments to overcome the high lethality of the available animal model. In addition, the number of variants with unknown significance is increasing in clinical settings. This study presents the generation of a cellular disease model by knocking out the PMM2 gene in the hepatoma HepG2 cell line using CRISPR-Cas9 gene editing. The HepG2 knockout model accurately replicates the PMM2-CDG phenotype, exhibiting a complete absence of PMM2 protein and mRNA, a 90% decrease in PMM enzymatic activity, and altered ICAM-1, LAMP1 and A1AT glycoprotein patterns. The evaluation of PMM2 disease-causing variants validates the model's utility for studying new PMM2 clinical variants, providing insights for diagnosis and potentially for evaluating therapies. A CRISPR-Cas9-generated HepG2 knockout model accurately recapitulates the PMM2-CDG phenotype, providing a valuable tool for assessing disease-causing variants and advancing therapeutic strategies., This work was funded by Instituto de Salud Carlos III (ISCIII), European Regional Development Fund [PI22/00699] to BP. The CIBER de Enfermedades Raras is an initiative from the ISCIII (Spain).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Expanding the genetic landscape of inherited metabolic diseases using long-read sequencing and transcriptomic profiling

  • Soriano-Sexto, Alejandro
  • Sánchez-Lijarcio, Obdulia
  • Beccari, Leonardo
  • Castejón-Fernández, Natalia
  • Leal, Fátima
  • Alcaide, Patricia
  • de la Morena-Barrio, Belén
  • Bahíllo-Curieses, María del Pilar
  • Correcher, Patricia
  • Hencke-Tresbach, Rafael
  • López, Laura
  • Martín-Hernández, Elena
  • Yahyaoui, Raquel
  • Ugarte, Magdalena
  • Rodríguez-Pombo, Pilar
  • Pérez, Belén
Although next-generation sequencing has emerged as a powerful tool for diagnosing rare diseases (RD), many cases of inherited metabolic diseases (IMD) remain unsolved, hindering the diagnosis, clinical and therapeutic management of the patients. The primary aim of this study is to address the most elusive cases by applying long-read sequencing (LRS) targeted to the gene of interest on seven patients (FARS2, GYS2, PEX1, SLC2A1, AGL, ACAT1, and ACADM), identifying six novel pathogenic variants including two intronic variants, a structural variant and three transposable elements (TE) insertions. In addition, we have demonstrated the effect on splicing of an exonic variant previously reported as missense. Functional genetic tests specific for the expected effect of each variant of uncertain significance were designed, such as minigenes analysis or chromatin conformation capture assay. From the TE insertions, two were located in the genomic region of GYS2 or PEX1, causing a reduction in their mRNA expression. The third was located 7.6 kb downstream of SLC2A1; it alters the interaction between the SLC2A1 promoter and its distal regulatory element via the establishment of a loop with the 3' border of the native topologically associating domain. This study shows that the combination of LRS and functional genetic assays confers a powerful approach for expanding the mutational spectrum of IMD, adding data to improve the diagnosis of this large group of RD., This work was funded by the Instituto de Salud Carlos III (ISCIII), European Regional Development Fund [PI22/00699] to BP. The CIBER de Enfermedades Raras is an initiative from the ISCIII (Spain). CEDEM gratefully acknowledges the support of Fundación Ramón Areces. R. H. Tresbach was awarded a grant from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq - Brasil - Process n. 200811/2024